Author’s response to reviews

Title: ATR-101, a selective ACAT1 inhibitor, decreases ACTH-stimulated cortisol concentrations in dogs with naturally occurring Cushing’s syndrome

Authors:

Daniel Langlois (langlo21@cvm.msu.edu)
Michele Fritz (fritzmi2@msu.edu)
William Schall (schall@cvm.msu.edu)
N. Olivier (olivier@cvm.msu.edu)
Rebecca Smedley (smedley1@dcpah.msu.edu)
Paul Pearson (pearson@p3pharma.com)
Marc Bailie (marc.bailie@inds-inc.com)
Stephen Hunt III (hunt@millendo.com)

Version: 2 Date: 24 Apr 2018

Author’s response to reviews:

Please kindly include all authors emails on title page.
All email addresses are now included on title page.
Please kindly provide us the final clean version without track changes.
All track changes and highlighting have been removed as requested.

Robert J. Kemppainen (Reviewer 2): Lines 227-228. Can the authors provide any additional detail concerning the timing of the ACTH stimulation relative to when the ATR-101 dose was administered? For example, was the pre sample collected immediately after ATR-101 dosing? The authors note later in the manuscript that such timing may be important in interpreting test results (Lines 454-455).

The test was started immediately after the dogs were dosed with ATR-101. This has been added to the manuscript. Please see line 232.